Managers / Q1 2025 · view latest →
Enavate Sciences GP, LLC
CIK 0001953107 · 106 W 56TH ST., FLOOR 8, NEW YORK, NY, 10019 · 212-909-3022
Summary
Enavate Sciences GP, LLC reported $133M in U.S.-listed holdings across 6 positions for Q1 2025.
The portfolio is heavily concentrated: IMNM alone accounts for 24.2% of reported value.
Compared with Q4 2024, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $133M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SIONSIONNA THERAPEUTICS INC | NEW | +2.48M | 2.48M | +$26M | $26M |
| IMNMIMMUNOME INC | ADDED | +1.29M | 4.77M | −$5M | $32M |
| UPBUPSTREAM BIO INC | HELD | +0 | 2.46M | −$25M | $15M |
| CAMPCAMP4 THERAPEUTICS CORP | HELD | +0 | 3.79M | −$5M | $15M |
| CMPXCOMPASS THERAPEUTICS INC | HELD | +0 | 7.79M | +$4M | $15M |
| ZBIOZENAS BIOPHARMA INC | HELD | +0 | 3.76M | −$1M | $30M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2025
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | IMNMIMMUNOME INChistory → | COM | 24.18% | $32M | 4.77M |
| 2 | ZBIOZENAS BIOPHARMA INChistory → | COM | 22.39% | $30M | 3.76M |
| 3 | SIONSIONNA THERAPEUTICS INChistory → | COM | 19.53% | $26M | 2.48M |
| 4 | CAMPCAMP4 THERAPEUTICS CORPhistory → | COM | 11.41% | $15M | 3.79M |
| 5 | UPBUPSTREAM BIO INChistory → | COM | 11.34% | $15M | 2.46M |
| 6 | CMPXCOMPASS THERAPEUTICS INChistory → | COM | 11.15% | $15M | 7.79M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $352M | 7 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $507M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $328M | 7 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $177M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $133M | 6 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $139M | 5 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.